Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Contact: Hillis Christopher (principal investigator)
Recruiting
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
NCT06654336· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source
Contact: Theos Tsakiridis, Dr.
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment
NCT07697287· Phase 4· McMaster University· Source
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
NCT06908694· Phase 4· Hamilton Health Sciences Corporation· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· Phase 3· Incyte Corporation· Source
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402· Phase 1· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source
Contact: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
NCT05948865· Phase 1· Conjupro Biotherapeutics, Inc.· Source
Contact: Rosalyn Juergens, MD, PhD (principal investigator)
Active, not recruiting
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
NCT05482971· Phase 2· PharmaEssentia· Source
Recruiting
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616· Phase 3· University College, London· Source
Contact: Edna Wilson
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
NCT04557501· Phase 3· Centre hospitalier de l'Université de Montréal (CHUM)· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
NCT04421820· Phase 1/2· Bold Therapeutics, Inc.· Source
Contact: Carrie Ferguson
Active, not recruiting
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
NCT03715478· Phase 1/2· Canadian Myeloma Research Group· Source
Recruiting
Low-Dose Weekly vs High-Dose Cisplatin
NCT03649048· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Source
Contact: Brandon Meyers, MD
Active, not recruiting
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study Looking at Biomarkers in Ovarian Cancer
NCT03419689· University Health Network, Toronto· Source
Contact: Amit Oza, M.D.
Active, not recruiting
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
NCT03016338· Phase 2· University Health Network, Toronto· Source
Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Source
Contact: Sebastian Hotte
Active, not recruiting
Management of Castration-Resistant Prostate Cancer with Oligometastases
NCT02685397· Phase 2/3· Sir Mortimer B. Davis - Jewish General Hospital· Source
Recruiting
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
NCT02906943· University Health Network, Toronto· Source
Contact: Samanta Del Rossi
Active, not recruiting
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT03127631· McMaster University· Source
Active, not recruiting
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· Phase 3· University of Sydney· Source
Active, not recruiting
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353· Phase 3· AstraZeneca· Source
Active, not recruiting
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986· Phase 3· AstraZeneca· Source
Active, not recruiting
Prostate Advances in Comparative Evidence
NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source